GLP-1 receptor agonists are also promising drugs in the context of lowering the rates of DKD development and progression by virtue of their anti-inflammatory, antifibrotic, and natriuretic properties, in addition to their established metabolic and cardiovascular benefits. This evidence concerns the gene GLP1R and diabetic kidney disease.